CTNM — Contineum Therapeutics Inc
NASDAQ · Pharmaceuticals · Pharmaceuticals
- Latest Close
- $12.41
- 30-Day Move
- +9.0%
- Market Cap
- $439M
- Shares Outstanding
- 37,340,000
- P/B Ratio
- 1.6
- ROE
- -23.0%
Analyst consensus: Buy · 13 analysts
Contineum Therapeutics Inc
A read-only Alphactor snapshot forContineum Therapeutics Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-24
Topline snapshot
Latest Close
$12.41
30-Day Move
+9.0%
Market Cap
$439M
Shares Outstanding
37,340,000
P/B Ratio
1.6
ROE
-23.0%
$12.41
+9.0%last 90 delayed daily bars
90D High
$16.33
90D Low
$8.60
Avg Volume
277,327
Net margin is 45.4%, useful for comparing CTNM against peers in Pharmaceuticals.
CTNM is up 9.0% over the last 30 trading days shown on this page.
Latest operating income is $-68M, which helps anchor the headline ratios with an actual earnings figure.
Latest Close
$12.41
30-Day Move
+9.0%
Market Cap
$439M
Shares Outstanding
37,340,000
P/B Ratio
1.6
ROE
-23.0%
ROA
-21.7%
Operating Margin
32.1%
Net Margin
45.4%
Debt / Equity
0
Current Ratio
27.5
Latest Revenue
$0
Revenue
$0
Gross Profit
--
Operating Income
$-68M
Net Income
$-60M
Gross Margin
--
Net Margin
4544.0%
Current Ratio
27.50
Debt / Equity
0.00
Altman Z
16.24
Safe
Piotroski
2
Weak (0-3)
Cash Conversion
0.92x
Rule of 40
--
Insufficient data
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $0 | $-23M | $-24M | $-20M |
| 2023-12-31 | $50M | $16M | $23M | $19M |
| 2024-12-31 | $0 | $-51M | $-42M | $-33M |
| 2025-12-31 | $0 | $-68M | $-60M | $-56M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Qube Research & Technologies
Filed 2025-11-14
--
--
Two Sigma Advisers
Filed 2025-11-14
--
--
Vanguard Group
Filed 2026-01-29
$15M
+31.8%
FMR LLC (Fidelity)
Filed 2026-02-17
$9M
+0.0%
BlackRock
Filed 2024-08-13
$7M
--
Geode Capital Management
Filed 2025-11-12
$2M
+196.0%
Marshall Wace
Filed 2025-11-13
$2M
--
4.31
Consensus
Buy—
—
—
13
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.